1
|
Ji Y, Winter L, Navarro L, Ku MC, Periquito JS, Pham M, Hoffmann W, Theune LE, Calderón M, Niendorf T. Controlled Release of Therapeutics from Thermoresponsive Nanogels: A Thermal Magnetic Resonance Feasibility Study. Cancers (Basel) 2020; 12:cancers12061380. [PMID: 32471299 PMCID: PMC7352924 DOI: 10.3390/cancers12061380] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 05/23/2020] [Accepted: 05/25/2020] [Indexed: 12/16/2022] Open
Abstract
Thermal magnetic resonance (ThermalMR) accommodates radio frequency (RF)-induced temperature modulation, thermometry, anatomic and functional imaging, and (nano)molecular probing in an integrated RF applicator. This study examines the feasibility of ThermalMR for the controlled release of a model therapeutics from thermoresponsive nanogels using a 7.0-tesla whole-body MR scanner en route to local drug-delivery-based anticancer treatments. The capacity of ThermalMR is demonstrated in a model system involving the release of fluorescein-labeled bovine serum albumin (BSA-FITC, a model therapeutic) from nanometer-scale polymeric networks. These networks contain thermoresponsive polymers that bestow environmental responsiveness to physiologically relevant changes in temperature. The release profile obtained for the reference data derived from a water bath setup used for temperature stimulation is in accordance with the release kinetics deduced from the ThermalMR setup. In conclusion, ThermalMR adds a thermal intervention dimension to an MRI device and provides an ideal testbed for the study of the temperature-induced release of drugs, magnetic resonance (MR) probes, and other agents from thermoresponsive carriers. Integrating diagnostic imaging, temperature intervention, and temperature response control, ThermalMR is conceptually appealing for the study of the role of temperature in biology and disease and for the pursuit of personalized therapeutic drug delivery approaches for better patient care.
Collapse
Affiliation(s)
- Yiyi Ji
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbruck Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany; (Y.J.); (M.-C.K.); (J.S.P.); (M.P.)
| | - Lukas Winter
- Physikalisch-Technische Bundesanstalt (PTB), 10587 Berlin, Germany; (L.W.); (W.H.)
| | - Lucila Navarro
- Freie Universität Berlin, Institute of Chemistry and Biochemistry, 14195 Berlin, Germany; (L.N.); (L.E.T.); (M.C.)
- Instituto de Desarrollo Tecnológico para la Industria Química (INTEC), Universidad Nacional del Litoral (UNL)—Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Santa Fe 3000, Argentina
| | - Min-Chi Ku
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbruck Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany; (Y.J.); (M.-C.K.); (J.S.P.); (M.P.)
| | - João S. Periquito
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbruck Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany; (Y.J.); (M.-C.K.); (J.S.P.); (M.P.)
| | - Michal Pham
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbruck Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany; (Y.J.); (M.-C.K.); (J.S.P.); (M.P.)
| | - Werner Hoffmann
- Physikalisch-Technische Bundesanstalt (PTB), 10587 Berlin, Germany; (L.W.); (W.H.)
| | - Loryn E. Theune
- Freie Universität Berlin, Institute of Chemistry and Biochemistry, 14195 Berlin, Germany; (L.N.); (L.E.T.); (M.C.)
| | - Marcelo Calderón
- Freie Universität Berlin, Institute of Chemistry and Biochemistry, 14195 Berlin, Germany; (L.N.); (L.E.T.); (M.C.)
- POLYMAT and Applied Chemistry Department, Faculty of Chemistry, University of the Basque Country UPV/EHU, 20018 Donostia-San Sebastián, Spain
- IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Thoralf Niendorf
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbruck Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany; (Y.J.); (M.-C.K.); (J.S.P.); (M.P.)
- Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany
- Correspondence: ; Tel.: +49-30-9406-4505
| |
Collapse
|